Activity of imipenem/relebactam and comparators against KPC-producing Klebsiella pneumoniae and imipenem-resistant Pseudomonas aeruginosa.
Carbapenem-resistant
Imipenem/relebactam
K. pneumoniae
P. aeruginosa
Journal
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
ISSN: 1435-4373
Titre abrégé: Eur J Clin Microbiol Infect Dis
Pays: Germany
ID NLM: 8804297
Informations de publication
Date de publication:
29 Dec 2023
29 Dec 2023
Historique:
received:
23
05
2023
accepted:
05
12
2023
medline:
2
1
2024
pubmed:
2
1
2024
entrez:
29
12
2023
Statut:
aheadofprint
Résumé
Relebactam is a novel β-lactamase inhibitor, which, when combined with imipenem/cilastatin, is active against both class A and class C β-lactamases. To evaluate in vitro antimicrobial activity of imipenem/relebactam against a collection of recent clinical isolates of carbapenem-non-susceptible P. aeruginosa and K. pneumoniae ST258 and ST512 KPC producers belonging to different lineages from hospitals in Southern Spain. Six hundred and seventy-eight isolates were tested: 265 K. pneumoniae (230 ST512/KPC-3 and 35 ST258/KPC-3) and 413 carbapenem-non-susceptible P. aeruginosa. Imipenem, piperacillin/tazobactam, ceftazidime, cefepime, aztreonam, ceftolozane/tazobactam, meropenem, amikacin, ciprofloxacin, colistin, and ceftazidime/avibactam were used as comparators against P. aeruginosa. Against K. pneumoniae ceftazidime, cefepime, aztreonam, and ceftolozane/tazobactam were not tested, and tigecycline was studied instead. MICs were determined in duplicate by broth microdilution according to EUCAST guidelines. Imipenem/relebactam displayed potent in vitro activity against both sequence types of KPC-3-producing K. pneumoniae. MIC Imipenem/relebactam showed excellent activity against K. pneumoniae KPC-3. The activity of imipenem/relebactam against imipenem-resistant P. aeruginosa was moderate.
Identifiants
pubmed: 38157139
doi: 10.1007/s10096-023-04735-1
pii: 10.1007/s10096-023-04735-1
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s).
Références
World Health Organization (2018) Antimicrobial resistance. Fact sheet. WHO web page. https://www.who.int/news-room/fact-sheets/detail/antibiotic-resistance . Accessed 12 Dec 2023
Barrasa-Villar JI, Aibar-Remón C, Prieto-Andrés P, Mareca-Doñate R, Moliner-Lahoz J (2017) Impact on morbidity, mortality, and length of stay of hospital-acquired infections by resistant microorganisms. Clin Infect Dis 15(65):644–652. https://doi.org/10.1093/cid/cix411
doi: 10.1093/cid/cix411
Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL et al (2018) Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis 18:318–327. https://doi.org/10.1016/S1473-3099(17)30753-3
doi: 10.1016/S1473-3099(17)30753-3
pubmed: 29276051
Yahav D, Giske CG, Gramatniece A, Abodakpi H, Tam VH, Leibovici L (2020) New β-lactam-β-lactamase inhibitor combinations. Clin Microbiol Rev 34:1–61. https://doi.org/10.1128/CMR.00115-20
doi: 10.1128/CMR.00115-20
Horcajada JP, Montero M, Oliver A, Sorlí L, Luque S, Gómez-Zorrilla S et al (2019) Epidemiology and treatment of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections. Clin Microbiol Rev 32. https://doi.org/10.1128/CMR.00031-19
Navon-Venezia S, Kondratyeva K, Carattoli A (2017) Klebsiella pneumoniae: a major worldwide source and shuttle for antibiotic resistance. FEMS Microbiol Rev 41:252–275. https://doi.org/10.1093/FEMSRE/FUX013
doi: 10.1093/FEMSRE/FUX013
pubmed: 28521338
Pitout JDD, Nordmann P, Poirel L (2015) Carbapenemase-producing Klebsiella pneumoniae, a key pathogen set for global nosocomial dominance. Antimicrob Agents Chemother 59:5873–5884. https://doi.org/10.1128/AAC.01019-15
doi: 10.1128/AAC.01019-15
pubmed: 26169401
pmcid: 4576115
Lister PD, Wolter DJ, Hanson ND (2009) Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev 22:582–610. https://doi.org/10.1128/CMR.00040-09
doi: 10.1128/CMR.00040-09
pubmed: 19822890
pmcid: 2772362
Botelho J, Grosso F, Peixe L (2019) Antibiotic resistance in Pseudomonas aeruginosa - mechanisms, epidemiology and evolution. Drug Resist Updat 44:100640. https://doi.org/10.1016/j.drup.2019.07.002
doi: 10.1016/j.drup.2019.07.002
pubmed: 31492517
Bush K, Jacoby GA (2010) Updated functional classification of beta-lactamases. Antimicrob Agents Chemother 54:969–976. https://doi.org/10.1128/AAC.01009-09
doi: 10.1128/AAC.01009-09
pubmed: 19995920
World Health Organization (2017) WHO publishes list of bacteria for which new antibiotics are urgently needed WHO publishes list of bacteria for which new antibiotics are urgently needed. WHO web page. https://www.who.int/en/news-room/detail/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed . Accessed 12 December 2023
Livermore DM, Warner M, Mushtaq S (2013) Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa. J Antimicrob Chemother 68:2286–2290. https://doi.org/10.1093/JAC/DKT178
doi: 10.1093/JAC/DKT178
pubmed: 23696619
Campanella TA, Gallagher JC (2020) A clinical review and critical evaluation of imipenem-relebactam: evidence to date. Infect Drug Resist 13:4297–4308. https://doi.org/10.2147/IDR.S224228
doi: 10.2147/IDR.S224228
pubmed: 33268997
pmcid: 7701153
Motsch J, De Oliveira CUM, Stus V, Kö Ksal I, Lyulko O, Boucher HW et al (2020) RESTORE-IMI 1: A Multicenter, Randomized, Double-blind trial comparing efficacy and safety of imipenem/relebactam vs colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections. Clin Infect Dis 70:1799–1808. https://doi.org/10.1093/CID/CIZ530
doi: 10.1093/CID/CIZ530
pubmed: 31400759
Titov I, Wunderink RG, Roquilly A, Rodríguez Gonzalez D, David-Wang A, Boucher HW et al (2021) A randomized, double-blind, multicenter trial comparing efficacy and safety of imipenem/cilastatin/relebactam versus piperacillin/tazobactam in adults with hospital-acquired or ventilator-associated bacterial pneumonia (RESTORE-IMI 2 study). Clin Infect Dis 73:e4539–e4548. https://doi.org/10.1093/CID/CIAA803
doi: 10.1093/CID/CIAA803
pubmed: 32785589
PIRASOA (2014) PIRASOA programme, an antimicrobial stewardship programme implemented in hospitals of the public health system of Andalusia, Spain. Junta Andalucía, web page. http://pirasoa.iavante.es/ . Accessed 12 Dec 2023
Rodríguez-Baño J, Pérez-Moreno MA, Peñalva G, Garnacho-Montero J, Pinto C, Salcedo I et al (2019) Outcomes of the PIRASOA programme, an antimicrobial stewardship programme implemented in hospitals of the public health system of Andalusia, Spain: an ecological study of time-trend analysis. Clin Microbiol Infect. https://doi.org/10.1016/j.cmi.2019.07.009
Ewels P, Magnusson M, Lundin S, Käller M (2016) MultiQC: summarize analysis results for multiple tools and samples in a single report. Bioinformatics 32:3047–3048. https://doi.org/10.1093/BIOINFORMATICS/BTW354
doi: 10.1093/BIOINFORMATICS/BTW354
pubmed: 27312411
pmcid: 5039924
Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS et al (2012) SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. J Comput Biol 19:455–477. https://doi.org/10.1089/cmb.2012.0021
doi: 10.1089/cmb.2012.0021
pubmed: 22506599
pmcid: 3342519
Gurevich A, Saveliev V, Vyahhi N, Tesler G (2013) Genome analysis QUAST: quality assessment tool for genome assemblies. 29:1072–1075. https://doi.org/10.1093/bioinformatics/btt086
Feldgarden M, Brover V, Gonzalez-Escalona N, Frye JG, Haendiges J, Haft DH et al AMRFinderPlus and the reference gene catalog facilitate examination of the genomic links among antimicrobial resistance, stress response, and virulence. Sci Rep 11:12728. https://doi.org/10.1038/s41598-021-91456-0
López-Causapé C, Mette Sommer L, Cabot G, Rubio R, Ocampo-Sosa AA, Krogh Johansen H et al, Evolution of the Pseudomonas aeruginosa mutational resistome in an international cystic fibrosis clone OPEN. https://doi.org/10.1038/s41598-017-05621-5
Standardization IO (2006) Clinical laboratory testing and in vitro diagnostic test systems - susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility test devices - part 1: reference method for testing the in vitro activity of antim, Geneva, Switzerland
The European Committee on Antimicrobial Susceptibility Testing(2021) Routine and extended internal quality control for MIC determination and disk diffusion as recommended by EUCAST Version 11.0. https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/QC/v_11.0_EUCAST_QC_tables_routine_and_extended_QC_pdf.pdf. Accessed 12 Dec 2023
The European Committee on Antimicrobial Susceptibility Testing (2021) Breakpoint tables for interpretation of MICs and zone diameters Version 11.0
Canver MC, Satlin MJ, Westblade LF, Kreiswirth BN, Chen L, Robertson A et al (2019) Activity of imipenem-relebactam and comparator agents against genetically characterized isolates of carbapenem-resistant Enterobacteriaceae. Antimicrob Agents Chemother:63. https://doi.org/10.1128/AAC.00672-19
Hernández-García M, García-Castillo M, Bou G, Cercenado E, Delgado-Valverde M, Oliver A et al (2022) Imipenem-relebactam susceptibility in Enterobacterales isolates recovered from ICU patients from Spain and Portugal (SUPERIOR and STEP studies). Microbiol Spectr:10. https://doi.org/10.1128/SPECTRUM.02927-22
Galani I, Souli M, Nafplioti K, Adamou P, Karaiskos I, Giamarellou H et al (2019) In vitro activity of imipenem-relebactam against non-MBL carbapenemase-producing Klebsiella pneumoniae isolated in Greek hospitals in 2015-2016. Eur J Clin Microbiol Infect Dis 38:1143–1150. https://doi.org/10.1007/S10096-019-03517-Y
doi: 10.1007/S10096-019-03517-Y
pubmed: 30825054
Vázquez-Ucha JC, Seoane-Estévez A, Rodiño-Janeiro BK, González-Bardanca M, Conde-Pérez K, Martínez-Guitián M et al (2021) Activity of imipenem/relebactam against a Spanish nationwide collection of carbapenemase-producing Enterobacterales. J Antimicrob Chemother 76:1498–1510. https://doi.org/10.1093/JAC/DKAB043
doi: 10.1093/JAC/DKAB043
pubmed: 33677560
Shields RK, Chen L, Cheng S, Chavda KD, Press EG, Snyder A et al (2017) Emergence of ceftazidime-avibactam resistance due to plasmid-borne blaKPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections. Antimicrob Agents Chemother:61. https://doi.org/10.1128/AAC.02097-16
Haidar G, Clancy CJ, Shields RK, Hao B, Cheng S, Nguyen MH (2017) Mutations in blaKPC-3 that confer ceftazidime-avibactam resistance encode novel KPC-3 variants that function as extended-spectrum β-lactamases. Antimicrob Agents Chemother:61. https://doi.org/10.1128/AAC.02534-16
Haidar G, Clancy CJ, Chen L, Samanta P, Shields RK, Kreiswirth BN et al (2017) Identifying spectra of activity and therapeutic niches for ceftazidime-avibactam and imipenem-relebactam against carbapenem-resistant Enterobacteriaceae. Antimicrob Agents Chemother:61. https://doi.org/10.1128/AAC.00642-17
Gaibani P, Bianco G, Amadesi S, Boattini M, Ambretti S, Costa C (2022) Increased blaKPC Copy Number and OmpK35 and OmpK36 porins disruption mediated resistance to imipenem/relebactam and meropenem/vaborbactam in a KPC-producing Klebsiella pneumoniae clinical isolate. Antimicrob Agents Chemother:66. https://doi.org/10.1128/aac.00191-22
Gaibani P, Giani T, Bovo F, Lombardo D, Amadesi S, Lazzarotto T et al (2022) Resistance to ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam in Gram-negative MDR Bacilli: molecular mechanisms and susceptibility testing. Antibiotics:11. https://doi.org/10.3390/ANTIBIOTICS11050628
Hernández-García M, García-Castillo M, Melo-Cristino J, Pinto MF, Gonçalves E, Alves V et al (2022) In vitro activity of imipenem/relebactam against Pseudomonas aeruginosa isolates recovered from ICU patients in Spain and Portugal (SUPERIOR and STEP studies). J Antimicrob Chemother:77. https://doi.org/10.1093/JAC/DKAC298
Zhang H, Jia P, Zhu Y, Zhang G, Zhang J, Kang W, et al. Susceptibility to imipenem/relebactam of Pseudomonas aeruginosa and Acinetobacter baumannii isolates from Chinese intra-abdominal, respiratory and urinary tract infections: SMART 2015 to 2018. Infect Drug Resist;14:3509. https://doi.org/10.2147/IDR.S325520
Young K, Painter RE, Raghoobar SL, Hairston NN, Racine F, Wisniewski D et al (2019) In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa. BMC Microbiol 19:1–14. https://doi.org/10.1186/s12866-019-1522-7
doi: 10.1186/s12866-019-1522-7
Fraile-Ribot PA, Zamorano L, Orellana R, Del Barrio-Tofiño E, Sánchez-Diener I, Cortes-Lara S, et al. Activity of imipenem-relebactam against a large collection of Pseudomonas aeruginosa clinical isolates and isogenic-lactam-resistant mutants. 2020
doi: 10.1128/AAC.02165-19
Gomis-Font MA, Cabot G, López-Argüello S, Zamorano L, Juan C, Moyá B et al, Comparative analysis of in vitro dynamics and mechanisms of ceftolozane/tazobactam and imipenem/relebactam resistance development in Pseudomonas aeruginosa XDR high-risk clones. https://doi.org/10.1093/jac/dkab496
Rodríguez-Martínez JM, Poirel L, Nordmann P (2009) Extended-spectrum cephalosporinases in Pseudomonas aeruginosa. Antimicrob Agents Chemother 53:1766–1771. https://doi.org/10.1128/AAC.01410-08
doi: 10.1128/AAC.01410-08
pubmed: 19258272
pmcid: 2681535
Gomis-Font MA, Pitart C, del Barrio-Tofiño E, Zboromyrska Y, Cortes-Lara S, Mulet X et al (2021) Emergence of resistance to novel cephalosporin-β-lactamase inhibitor combinations through the modification of the Pseudomonas aeruginosa MexCD-OprJ efflux pump. Antimicrob Agents Chemother:65. https://doi.org/10.1128/AAC.00089-21
Morita Y, Sobel ML, Poole K (2006) Antibiotic inducibility of the MexXY multidrug efflux system of Pseudomonas aeruginosa: involvement of the antibiotic-inducible PA5471 gene product. J Bacteriol 188:1847–1855. https://doi.org/10.1128/JB.188.5.1847-1855.2006
doi: 10.1128/JB.188.5.1847-1855.2006
pubmed: 16484195
pmcid: 1426571
Hay T, Fraud S, Lau CHF, Gilmour C, Poole K (2013) Antibiotic inducibility of the mexXY multidrug efflux operon of Pseudomonas aeruginosa: involvement of the MexZ anti-repressor ArmZ. PloS One:8. https://doi.org/10.1371/JOURNAL.PONE.0056858
Yamamoto M, Ueda A, Kudo M, Matsuo Y, Fukushima J, Nakae T et al (2009) Role of MexZ and PA5471 in transcriptional regulation of mexXY in Pseudomonas aeruginosa. Microbiology 155:3312–3321. https://doi.org/10.1099/MIC.0.028993-0
doi: 10.1099/MIC.0.028993-0
pubmed: 19589837
Fajardo A, Hernando-Amado S, Oliver A, Ball G, Filloux A, Martinez JL (2014) Characterization of a novel Zn
doi: 10.1093/JAC/DKU267
pubmed: 25185138
Sobel ML, Neshat S, Poole K (2005) Mutations in PA2491 (mexS) promote MexT-dependent mexEF-oprN expression and multidrug resistance in a clinical strain of Pseudomonas aeruginosa. J Bacteriol 187:1246–1253. https://doi.org/10.1128/JB.187.4.1246-1253.2005
doi: 10.1128/JB.187.4.1246-1253.2005
pubmed: 15687188
pmcid: 545639
Lorusso AB, Carrara JA, Barroso CDN, Tuon FF, Faoro H (2022) Role of efflux pumps on antimicrobial resistance in Pseudomonas aeruginosa. Int J Mol Sci:23. https://doi.org/10.3390/IJMS232415779
Cao L, Srikumar R, Poole K (2004) MexAB-OprM hyperexpression in NalC-type multidrug-resistant Pseudomonas aeruginosa: identification and characterization of the nalC gene encoding a repressor of PA3720-PA3719. Mol Microbiol 53:1423–1436. https://doi.org/10.1111/J.1365-2958.2004.04210.X
doi: 10.1111/J.1365-2958.2004.04210.X
pubmed: 15387820
Muller C, Plésiat P, Jeannot K (2011) A two-component regulatory system interconnects resistance to polymyxins, aminoglycosides, fluoroquinolones, and β-lactams in Pseudomonas aeruginosa. Antimicrob Agents Chemother 55:1211–1221. https://doi.org/10.1128/AAC.01252-10
doi: 10.1128/AAC.01252-10
pubmed: 21149619
Handfield J, Gagnon L, Dargis M, Huletsky A (1997) Sequence of the ponA gene and characterization of the penicillin-binding protein 1A of Pseudomonas aeruginosa PAO1. Gene 199:49–56. https://doi.org/10.1016/S0378-1119(97)00345-4
doi: 10.1016/S0378-1119(97)00345-4
pubmed: 9358038
Glen KA, Lamont IL (2021) β-lactam resistance in Pseudomonas aeruginosa: current status, future prospects. Pathog (Basel, Switzerland) 10. https://doi.org/10.3390/PATHOGENS10121638